Claire Raskino

Ipsen (France) — France

Immunology and Microbiology · Life Sciences

14h-index1.1kcitations24works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(12), HIV/AIDS Research and Interventions(10), HIV/AIDS drug development and treatment(7), Liver Diseases and Immunity(5), Liver Disease Diagnosis and Treatment(4)

Publications24 total

P36 Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis (PBC) with two years of treatment with elafibranor
2025
Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years
Zeitschrift für Gastroenterologie·2025· 1 cited
P199 Long-term efficacy and safety of elafibranor in primary biliary cholangitis: interim results from the open-label extension of the ELATIVE® trial
2025
THU-333 Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor
Journal of Hepatology·2025
T‐1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide‐Containing Treatment Regimen
The Journal of Infectious Diseases·2005· 93 cited
Short‐Term Safety and Antiretroviral Activity of T‐1249, a Second‐Generation Fusion Inhibitor of HIV
The Journal of Infectious Diseases·2004· 126 citedOpen Access
Prevalence of Chemokine and Chemokine Receptor Polymorphisms in Seroprevalent Children With Symptomatic HIV-1 Infection in the United States
JAIDS Journal of Acquired Immune Deficiency Syndromes·2004· 9 cited
Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors
The Pediatric Infectious Disease Journal·2004· 9 cited
Genetic Influence of<i>CCR5, CCR2,</i>and<i>SDF1</i>Variants on Human Immunodeficiency Virus 1 (HIV‐1)–Related Disease Progression and Neurological Impairment, in Children with Symptomatic HIV‐1 Infection
The Journal of Infectious Diseases·2003· 72 cited
Predicting HIV Disease Progression in Children Using Measures of Neuropsychological and Neurological Functioning
PEDIATRICS·2000· 61 cited
The<i>CCR5Δ32</i>Allele Slows Disease Progression of Human Immunodeficiency Virus–1–Infected Children Receiving Antiretroviral Treatment
The Journal of Infectious Diseases·2000· 41 citedOpen Access
Neurologic, Neurocognitive, and Brain Growth Outcomes in Human Immunodeficiency Virus-Infected Children Receiving Different Nucleoside Antiretroviral Regimens
PEDIATRICS·1999· 58 cited
Virologic and Immunologic Response to Nucleoside Reverse‐Transcriptase Inhibitor Therapy among Human Immunodeficiency Virus–Infected Infants and Children
The Journal of Infectious Diseases·1999· 25 citedOpen Access
Neurocognitive/Neurological Outcomes in HIV-infected Children Receiving Different Nucleoside Antiretroviral Regimens (ACTG Protocol 152) ♦ 832
Pediatric Research·1998· 1 citedOpen Access
Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children
New England Journal of Medicine·1997· 156 cited
Clinical and Laboratory Characteristics of a Large Cohort of Symptomatic, Human Immunodeficiency Virus-infected Infants and Children
The Pediatric Infectious Disease Journal·1996· 68 cited
Variations in the use of coronary arteriography in the UK: the RITA trial coronary arteriogram register
QJM·1995· 25 cited
Prothrombin Activation Fragment 1 + 2 and Thrombin Antithrombin III Complexes in Patients with Angina Pectoris: Relation to the Presence and Severity of Coronary Atherosclerosis
Thrombosis and Haemostasis·1993· 76 cited
Factors affecting the precision of warfarin treatment.
Journal of Clinical Pathology·1992· 9 citedOpen Access
Factors affecting the maintenance dose of warfarin.
Journal of Clinical Pathology·1992· 178 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Janet A. Englund(8), Carol J. Baker(8), Ross E. McKinney(7), Stephen A. Spector(5), Deborah A. Pearson(4), Kris V. Kowdley(4), Christopher L. Bowlus(4), Christophe Corpechot(4), Marlyn J. Mayo(4), Mark G. Swain(4), Valeria Cranham(4), Jörn M. Schattenberg(4), Simon G. Thompson(3), Marta H. Lifschitz(3), Molly L. Nozyce(3), Charlene F. Barroga(3), Michael D. Hughes(3), Paul Palumbo(3), Michael A. Heneghan(3), Cynthia Levy(3)